Rivaroxaban Market, by Strength (10 mg, 15 mg, and 20 mg), by Application (Deep Vein Thrombosis Prophylaxis and Pulmonary Embolism), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Region - Global Forecast to 2026

  • Published On : Jul 2018 |
  • Pages : 150 Pages |
  • Format : CMI Insight PPT Format CMI Insight PDF Format

Rivaroxaban Market Insights – Stop the Clot

Rivaroxaban is a Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) that is marketed as Xarelto. Anticoagulant medicines are potent therapeutic agents used in the prevention or treatment of serious illnesses and potentially life-threatening conditions associated with blood coagulation. Rivaroxaban was discovered by Bayer and is being jointly developed with Janssen Research & Development, LLC.

Xarelto is approved for indications such as stroke prevention in non-valvular atrial fibrillation, pulmonary embolism, deep vein thrombosis, prevention of recurrent venous thromboembolism (VTE), prevention of VTE after elective hip and knee replacement surgery, and secondary prevention after acute coronary syndrome.

In September 2008, the drug received CE approval for venous thromboembolism in adults undergoing knee and hip replacement surgeries and in 2011, it was approved by the U.S. Food and Drug Administration (FDA) for the same indication. Xarelto is approved in over 130 countries by respective regulatory bodies.

Table 1. Timeline of Rivaroxaban Approval

Year of Approval Indication Region
Sep 2008 Prevention of venous thromboembolism (VTE) following elective hip or knee-joint replacement surgery Canada, Europe, and several other countries
Dec 2011 Stroke prevention in patients with atrial fibrillation, treatment of deep vein thrombosis (DVT) and prevention of recurring DVT and pulmonary embolism Europe
July 2011 DVT prophylaxis in adult patients following elective hip or knee joint replacement surgery U.S.
Nov 2011 Reducing the risk of stroke in patients with atrial fibrillation U.S.
Jan 2012 Prophylaxis of stroke and systemic embolism in patients with non-valvular atrial fibrillation Japan
May 2013 Prevention of atherothrombotic events after acute coronary syndrome (ACS) in patients with elevated cardiac biomarkers in combination with standard antiplatelet therapy Europe
May 2015 Prevention of stroke and systematic embolism in patients with non atrial fibrillation China
Sep 2015 Treatment for recurring deep vein thrombosis Japan

Source: Bayer Annual Report (2008-2017)

The global rivaroxaban market size is estimated to be valued at US$ 5,653 million in 2017 and is expected to witness a CAGR of 1.5% over the forecast period (2018 – 2026) on account of patent expiry during the forecast period.

Figure 1. Global Rivaroxaban Market Share, By Region

Source: Coherent Market Insights Analysis (2018)

Increasing number of hip and knee replacement surgeries are augmenting rivaroxaban market growth

As an anti-coagulant drug is intended to be used for the prevention and treatment of embolism and non-hemorrhagic stroke, increasing incidences of such medical conditions are expected to boost the rivaroxaban market growth over the forecast period.

For instance, according to the Centers for Disease Control and Prevention (CDC) data of 2015, around 900,000 people are expected to be affected by venous thromboembolism each year in the U.S. Furthermore, the number of affected individuals are expected to increase by around 5% to 8% in the U.S., owing to several genetic risk factors such as condition known as inherited thrombophilia.

Moreover, endeavor to use the drug for additional indication is expected to support the market growth. For instance, Swiss Paraplegic Centre Nottwil was investigating the drug for cervical spinal cord injury, which is in phase 4 clinical trial as on December 2017. Furthermore, Onze Lieve Vrouw Hospital and AZ Sint-Jan AV are conducting clinical trial of 10 mg rivaroxaban for the indication of chronic renal failure.

Another major factor negatively affecting the rivaroxaban market growth is patent expiration of the drug Xarelto. Patent expiration leads to the manufacturing of generic drugs, which can be leveraged by the generic manufactures. The availability of generic drugs is expected to lower the treatment cost making it affordable to a wider class of individuals.

Dreadful injuries caused due to Xarelto, has led the company face many legal issues in the U.S. market. For instance, as of January 30, 2018, Bayer Group had been served in the U.S. with around 22,000 claims of Xarelto for personal injuries from the use of Xarelto, which includes cerebral, gastrointestinal or other bleeding and death causes. On clearance of the claims, the market of the product is expected to be affected in terms of revenue.

Rivaroxaban Market Regional Outlook

On the basis of region, the global rivaroxaban market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America is holding dominant position in the global rivaroxaban market, owing to high product sales coupled with high cost of the drug. For instance, the treatment cost for rivaroxaban is around US$ 450-500 per month and around 45% of the market revenue generated in 2017 was from the U.S. market.

Moreover, according to an article published in the ‘Journal of The American Heart Association’, 2018, a hospital-based survey suggested the global burden of disability-adjusted life-years from venous thromboembolism to be 7.6 per 100,000 person-years. The high rate of mortality associated with venous thromboembolism increases the demand for drugs such as rivaroxaban.

Key players in the global rivaroxaban market

Major players operating in the global rivaroxaban market include Janssen Pharmaceuticals Inc. and Bayer AG.

Market players strategize to strengthen their foot hold in the market in spite of high cost by implementing cost-effective treatment schemes. For instance, Janssen Pharmaceuticals offer Xarelto manufacturer coupon or patient assistance program to lower the cost of the drug.

Rivaroxaban is an anti-coagulant medication marketed under the brand name Xarelto by Janssen Pharmaceuticals Inc., a subsidiary of Johnson & Johnson. The report segments the rivaroxaban market based on strength of the drug, application, distribution channel, and region. The product is segmented into 10 mg, 15 mg, and 20 mg on the basis of strength and by application, it is segmented into deep venous thrombosis and pulmonary embolism. The report on rivaroxaban is intended to target the innovators and developers to provide in-depth analysis of the present market and the expected market scenario after the patent expiration. This report compiles the global rivaroxaban market overview, dynamics, opportunities, regional analysis, and market players.

Market Dynamics

Increasing clinical trials for the expansion of present indication of rivaroxaban is expected to be the key factor driving the rivaroxaban market growth over the forecast period. For instance, as per the data of clinical trials accessed on July 2018, Swiss Paraplegic Centre was evaluating rivaroxaban for cervical spinal cord injuries, with its successful entry in phase IV. The high cost of patented drug is a major factor contributing to high revenues and compound annual growth rate (CAGR). However, patent expiration of the drug in 2021 is expected to decrease the company revenues with the entry of new entrants with generic version of the drug at lower cost. The adverse effects of the drug such as risk of bleeding in patients leading to serious and fatal conditions are expected to restrain rivaroxaban market growth. Moreover, alternative therapies such as warfarin and heparin are cheaper, as compared to rivaroxaban and are expected to hamper growth of the global rivaroxaban market.

Key features of the study:

  • This report provides in-depth analysis of the rivaroxaban market and provides market size (US$ Million) and compound annual growth rate (CAGR (%)) for the forecast period: 2018 – 2026, considering 2017 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global rivaroxaban market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Janssen Pharmaceuticals Inc. and Bayer AG
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, distribution channel upgrades, market expansion, and marketing tactics
  • The global rivaroxaban market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors and suppliers of rivaroxaban, research and consulting firms, new entrants, and financial analysts
  • Various strategy matrices used in analyzing the rivaroxaban market would provide stakeholders vital inputs to make strategic decisions accordingly

Detailed Segmentation:

  • Global Rivaroxaban Market, By Strength:
    • 10 mg
    • 15 mg
    • 20 mg
  • Global Rivaroxaban Market, By Application:
    • Deep Vein Thrombosis Prophylaxis
    • Pulmonary Embolism
  • Global Rivaroxaban Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Rivaroxaban Market, By Region:
    • North America
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By country:
        • Germany
        • U.K.
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Middle East
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Strength:
        • 10 mg
        • 15 mg
        • 20 mg
      • By Application:
        • Deep Vein Thrombosis Prophylaxis
        • Pulmonary Embolism
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By country:
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
      • Janssen Pharmaceuticals Inc.*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Bayer AG

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
    • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Strength
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Industry Trends
    • Regulatory Scenario
    • Epidemiology
  4. Global Rivaroxaban Market, By Product Type, 2016 – 2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • 10 mg
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • 15 mg
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • 20 mg
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  5. Global Rivaroxaban Market, By Application, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Deep Vein Thrombosis Prophylaxis
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Pulmonary Embolism
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  6. Global Rivaroxaban Market, By Distribution Channel, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, 2017 – 2026
      • Segment Trends
    • Hospitals Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2026, (US$ Million)
  7. Global Rivaroxaban Market, By Regions, 2016–2026, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2018 and 2026 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Strength, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Application, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2026, (US$ Million)
      • Market Size and Forecast, By Country, 2016 - 2026, (US$ Million)
        • Northern Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Company Profiles
      • Janssen Pharmaceuticals Inc.*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About Us and Sales Contact

*Browse 22 market data tables and 20 figures on “Rivaroxaban Market - Global forecast to 2026”.

Research Methodology

Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:

  • Primary Research (Trade Surveys and Experts Interviews)
  • Desk Research
  • Proprietor Data Analytics Model

In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.


Smiley face

Coherent Market Insights desk research is based on a principle set of research techniques:

  • National level desk research: It Includes research analysis of regional players, regional regulatory bodies, regional trade associations, and regional organization.
  • Multinational level desk research: The research team keeps a track of multinational players, global regulatory bodies, global trade associations, and global organization.

Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:

  • Governmental bodies, National and international social welfare institutions, and organizations creating economic policies among others.
  • Trade association, National and international media and trade press.
  • Company Annual reports, SEC filings, Corporate Presentations, press release, news, and specification sheet of manufacturers, system integrators, brick and mortar - distributors and retailers, and third party online commerce players.
  • Scientific journals, and other technical magazines and whitepapers.

Smiley face

Preliminary Data Mining

The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.

Data Standardization:

Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.

Coherent Statistical model

We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:

  • Micro-economic indicators
  • Macro-economic indicators
  • Environmental indicators
  • Socio-political indicators
  • Technology indicators

Data Processing

Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.

Data Validation

This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:

  • It provides first-hand information on the market dynamics, outlook, and growth parameters.
  • Industry experts validates the estimates which helps the company to cement the on-going research study.
  • Primary research includes online surveys, face-to face interviews, and telephonic interviews.

The primary research is conducted with the ecosystem players including, but not limited to:

  • Raw Material Suppliers
  • Manufacturers
  • System Integrators
  • Distributors
  • End-users

Choose License Type

"How Can I Help You" ?

Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.

[email protected]

Key Benefits

  • Custom Research Solution

    Talk to our research consultant to design an exclusive report as per your research needs.

  • Customer Fulfilment

    We aim to fulfil client's research demands with tailored research solutions.

  • Quick Turnaround Time Reports

    We aim to provide research studies in quickest turnaround time and in a much cost effective manner.

  • 360-degree Approach

    We cover each industry from supply and demand side with an aim to provide a most holistic research study.

  • Assured Quality

    We strive to provide most accurate and reliable research findings in our research reports.